Literature DB >> 23831030

Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.

Henry Garcia1, Jeffrey C Miecznikowski, Alfiya Safina, Mairead Commane, Anja Ruusulehto, Sami Kilpinen, Robert W Leach, Kristopher Attwood, Yan Li, Seamus Degan, Angela R Omilian, Olga Guryanova, Olympia Papantonopoulou, Jianmin Wang, Michael Buck, Song Liu, Carl Morrison, Katerina V Gurova.   

Abstract

The facilitates chromatin transcription (FACT) complex is involved in chromatin remodeling during transcription, replication, and DNA repair. FACT was previously considered to be ubiquitously expressed and not associated with any disease. However, we discovered that FACT is the target of a class of anticancer compounds and is not expressed in normal cells of adult mammalian tissues, except for undifferentiated and stem-like cells. Here, we show that FACT expression is strongly associated with poorly differentiated aggressive cancers with low overall survival. In addition, FACT was found to be upregulated during in vitro transformation and to be necessary, but not sufficient, for driving transformation. FACT also promoted survival and growth of established tumor cells. Genome-wide mapping of chromatin-bound FACT indicated that FACT's role in cancer most likely involves selective chromatin remodeling of genes that stimulate proliferation, inhibit cell death and differentiation, and regulate cellular stress responses.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23831030      PMCID: PMC5886782          DOI: 10.1016/j.celrep.2013.06.013

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  37 in total

1.  A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

Authors:  D M Keller; X Zeng; Y Wang; Q H Zhang; M Kapoor; H Shu; R Goodman; G Lozano; Y Zhao; H Lu
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  Inflammation and p53: A Tale of Two Stresses.

Authors:  Andrei V Gudkov; Katerina V Gurova; Elena A Komarova
Journal:  Genes Cancer       Date:  2011-04

3.  Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells.

Authors:  James C Garbe; Sanchita Bhattacharya; Batul Merchant; Ekaterina Bassett; Karen Swisshelm; Heidi S Feiler; Andrew J Wyrobek; Martha R Stampfer
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

4.  Functional cooperation between FACT and MCM is coordinated with cell cycle and differential complex formation.

Authors:  Bertrand Chin-Ming Tan; Hsuan Liu; Chih-Li Lin; Sheng-Chung Lee
Journal:  J Biomed Sci       Date:  2010-02-16       Impact factor: 8.410

5.  Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines.

Authors:  Martha R Stampfer; James Garbe; Tarlochan Nijjar; Don Wigington; Karen Swisshelm; Paul Yaswen
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

6.  The transcript elongation factor FACT affects Arabidopsis vegetative and reproductive development and genetically interacts with HUB1/2.

Authors:  Ihab B Lolas; Kristiina Himanen; Jesper T Grønlund; Carina Lynggaard; Andreas Houben; Michael Melzer; Mieke Van Lijsebettens; Klaus D Grasser
Journal:  Plant J       Date:  2009-11-27       Impact factor: 6.417

Review 7.  The FACT chromatin modulator: genetic and structure/function relationships.

Authors:  Richard A Singer; Gerald C Johnston
Journal:  Biochem Cell Biol       Date:  2004-08       Impact factor: 3.626

8.  Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation.

Authors:  A J Brenner; M R Stampfer; C M Aldaz
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

9.  Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells.

Authors:  Henry Garcia; Daria Fleyshman; Katerina Kolesnikova; Alfiya Safina; Mairead Commane; Geraldine Paszkiewicz; Angela Omelian; Carl Morrison; Kateryna Gurova
Journal:  Oncotarget       Date:  2011-10

10.  FACT facilitates chromatin transcription by RNA polymerases I and III.

Authors:  Joanna L Birch; Bertrand C-M Tan; Kostya I Panov; Tatiana B Panova; Jens S Andersen; Tom A Owen-Hughes; Jackie Russell; Sheng-Chung Lee; Joost C B M Zomerdijk
Journal:  EMBO J       Date:  2009-02-12       Impact factor: 11.598

View more
  59 in total

1.  Structural analysis of nucleosomal barrier to transcription.

Authors:  Daria A Gaykalova; Olga I Kulaeva; Olesya Volokh; Alexey K Shaytan; Fu-Kai Hsieh; Mikhail P Kirpichnikov; Olga S Sokolova; Vasily M Studitsky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

2.  Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.

Authors:  Jayne Murray; Emanuele Valli; Denise M T Yu; Alan M Truong; Andrew J Gifford; Georgina L Eden; Laura D Gamble; Kimberley M Hanssen; Claudia L Flemming; Alvin Tan; Amanda Tivnan; Sophie Allan; Federica Saletta; Leanna Cheung; Michelle Ruhle; John D Schuetz; Michelle J Henderson; Jennifer A Byrne; Murray D Norris; Michelle Haber; Jamie I Fletcher
Journal:  Eur J Cancer       Date:  2017-07-20       Impact factor: 9.162

3.  FACT Inhibition Blocks Induction But Not Maintenance of Pluripotency.

Authors:  Zuolian Shen; Tim Formosa; Dean Tantin
Journal:  Stem Cells Dev       Date:  2018-11-28       Impact factor: 3.272

Review 4.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

5.  Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Authors:  Josephine Kam Tai Dermawan; Masahiro Hitomi; Daniel J Silver; Qiulian Wu; Poorva Sandlesh; Andrew E Sloan; Andrei A Purmal; Katerina V Gurova; Jeremy N Rich; Justin D Lathia; George R Stark; Monica Venere
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

6.  Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Authors:  Josephine Kam Tai Dermawan; Katerina Gurova; John Pink; Afshin Dowlati; Sarmishtha De; Goutham Narla; Neelesh Sharma; George R Stark
Journal:  Mol Cancer Ther       Date:  2014-07-15       Impact factor: 6.261

7.  Fine-Tuning of FACT by the Ubiquitin Proteasome System in Regulation of Transcriptional Elongation.

Authors:  Rwik Sen; Jannatul Ferdoush; Amala Kaja; Sukesh R Bhaumik
Journal:  Mol Cell Biol       Date:  2016-05-16       Impact factor: 4.272

8.  Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non-small cell lung cancer cells.

Authors:  Ning Song; Baohua Wang; Guishan Feng; Lin Duan; Shengfang Yuan; Weihua Jia; Yi Liu
Journal:  Oncol Lett       Date:  2019-01-14       Impact factor: 2.967

9.  Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.

Authors:  Heyu Song; Jiping Zeng; Shrabasti Roychoudhury; Pranjal Biswas; Bhopal Mohapatra; Sutapa Ray; Kayvon Dowlatshahi; Jing Wang; Vimla Band; Geoffrey Talmon; Kishor K Bhakat
Journal:  Mol Cancer Ther       Date:  2019-10-01       Impact factor: 6.261

10.  Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Authors:  Richard Lock; Hernan Carol; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Jianrong Wu; Andrei Purmal; Andrei Gudkov; Dias Kurmashev; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-09-21       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.